Nordic Life Science 1
TOP STORIES BUSINESS ACQU I SITIONS // AGREEMENTS
// COLLABORATIONS MED T E C H Bonalive opens new factory The new factory in Turku will enable up to ten times the production capacity. BONALIVE MANUFACTURES AND develops bone graft substitutes using bioactive glass that reduces the need for antibiotics. “In the future, we hope to work Karin Meyer, CEO of CTR, Anders Millerhovf, new CCO of CTC and CTR, and Suzanne Iverson Hemberg, new CEO of CTC. C A REER S Center for Translational Research announces leadership changes The changes include new CEOs for CTC Clinical Trial Consultants (CTC) and Toxicology Knowledge Team Sweden (TKT), and a new role as Chief Commercial Officer for CTC’s current CEO Anders Millerhovf. THE LARGEST COMPANY within the group, the full-service CRO CTC, has been led by Anders Millerhovf since 2015. He will now step into a new dual role as Chief Commercial Officer for CTC and Center for Translational Research (CTR), focusing on driving customer relations and business development for CTC as well as the entire corporate group under CTR. Suzanne Iverson Hemberg, the current CEO of TKT, will become CEO of CTC. She brings experience from both the corporate and public healthcare sectors, having previously held Senior Director positions in Laboratory Medicine at Sahlgrenska University Hospital as well as principal scientific and 20 | NORDICLIFESCIENCE.ORG middle management roles at AstraZeneca. She has a PhD in Pharmacology and Toxicology from the University of Toronto after which she undertook a postdoc in Molecular Toxicology at Karolinska Institutet. Anna Steneholm, who has worked as Senior Toxicology Consultant at TKT since 2022, will take the role as CEO of the company. Steneholm holds a PhD in Toxicology from Karolinska Institutet, and has previously held senior roles within toxicology in the chemical and petroleum industry, for example with the trade organisation Concawe and Nynas. “I am grateful for the opportunity to foster leadership through internal career development,” says Karin Meyer, CEO, CTR. NLS more closely with researchers and healthcare professionals in different fields to tackle this global challenge together,” says Marco Hautalahti, CEO, Bonalive. At the new factory, production, quality assurance, testing, and product development take place under one roof. This enables the company to better meet the international demand, and the company is currently expanding its activities, particularly in the US market. In recent years, Bonalive’s solutions have also seen use in Ukraine. Bioactive glass has been used to treat over 300 patients, particularly in cases of severely infected war wounds. “On the front line, wounds become infected quickly, and antibiotics may be less effective. Bonalive’s solutions support bone regeneration and provide a vital antimicrobial alternative in environments where treatment conditions are extremely demanding,” says Hautalahti. NLS Turku, Finland PHOTO EVA GARMENDIA